In:
Clinical Science, Portland Press Ltd., Vol. 123, No. 9 ( 2012-11-01), p. 545-546
Kurzfassung:
TRAIL [TNF (tumour necrosis factor)-related apoptosis-inducing ligand] is in clinical trials for the treatment of cancer. In the present issue of Clinical Science, Bernardi and co-workers report that the administration of TRAIL in mice fed on a high-fat diet resulted in reduced adiposity and improved metabolic responses to a glucose and insulin tolerance test compared with mice without TRAIL. The metabolic improvements were associated with a higher rate of apoptotic fat cells and with a reduction in the levels of pro-inflammatory cytokines. These results suggest that TRAIL could be an exciting new therapeutic for treating obesity, but further studies are required to determine its major mechanisms of action.
Materialart:
Online-Ressource
ISSN:
0143-5221
,
1470-8736
Sprache:
Englisch
Verlag:
Portland Press Ltd.
Publikationsdatum:
2012
